- Pharmaceutical Products
- Products By Brand Name
- Products By Dosage Form
- Products By Generic Name
- Products By Therapeutic Class
Find a product
Find Generic
Sitadus
Sitagliptin
Description:
Sitadus® (Sitagliptin) is an oral diabetes medicine that helps to control blood sugar levels. Sitadus tablet contains the active ingredient Sitagliptin which is a type of medicine called dipeptidyl peptidase-4 (DPP-4) inhibitor. It is used to treat people with type-2 or non-insulin dependent diabetes mellitus.
Sitadus® (Sitagliptin) is an oral diabetes medicine that helps to control blood sugar levels. Sitadus tablet contains the active ingredient Sitagliptin which is a type of medicine called dipeptidyl peptidase-4 (DPP-4) inhibitor. It is used to treat people with type-2 or non-insulin dependent diabetes mellitus.
Indications:
Sitadus® is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. It is also indicated for use in combination with Metformin, Sulfonylurea or Thiazolidinediones when diet and exercise plus the single agent does not provide adequate glycemic control.
Sitadus® is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. It is also indicated for use in combination with Metformin, Sulfonylurea or Thiazolidinediones when diet and exercise plus the single agent does not provide adequate glycemic control.
Mode of Action:
Sitagliptin inhibits dipeptidyl peptidase 4 (DPP-4), the enzyme responsible for the inactivation of the incretin hormones which are released into the blood circulation in response to food intake. Inhibition of DPP-4, results in higher levels of active incretin hormones, stimulating insulin release and reducing glucagon release in a glucose dependent manner.
Sitagliptin inhibits dipeptidyl peptidase 4 (DPP-4), the enzyme responsible for the inactivation of the incretin hormones which are released into the blood circulation in response to food intake. Inhibition of DPP-4, results in higher levels of active incretin hormones, stimulating insulin release and reducing glucagon release in a glucose dependent manner.
Other Brands From Same Therapeutic Class
